KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Income towards Parent Company: 2011-2024

Historic Income towards Parent Company for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$4.8 million.

  • Esperion Therapeutics' Income towards Parent Company fell 2.90% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 160.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 97.74% up from last year.
  • Esperion Therapeutics' Income towards Parent Company amounted to -$4.8 million in FY2024, which was up 97.74% from -$214.5 million recorded in FY2023.
  • Esperion Therapeutics' 5-year Income towards Parent Company high stood at -$4.8 million for FY2024, and its period low was -$273.1 million during FY2021.
  • Its 3-year average for Income towards Parent Company is -$151.9 million, with a median of -$214.5 million in 2023.
  • As far as peak fluctuations go, Esperion Therapeutics' Income towards Parent Company crashed by 89.55% in 2021, and later skyrocketed by 97.74% in 2024.
  • Esperion Therapeutics' Income towards Parent Company (MRY) stood at -$144.1 million in 2020, then tumbled by 89.55% to -$273.1 million in 2021, then increased by 13.47% to -$236.3 million in 2022, then rose by 9.21% to -$214.5 million in 2023, then surged by 97.74% to -$4.8 million in 2024.
  • Its Income towards Parent Company was -$4.8 million in FY2024, compared to -$214.5 million in FY2023 and -$236.3 million in FY2022.